Novo Nordisk has submitted an NDA to the FDA and a Marketing Authorization Application to the EMA for etavopivat, an investigational once-daily oral treatment for sickle cell disease in patients ages 12 and older.
The submissions are supported by results from the phase 3 HIBISCUS trial, in which etavopivat demonstrated a 27% reduction in annualized vaso-occlusive crises (VOCs) and delayed the time to first crisis by approximately four months compared to placebo. The trial also showed that 48.7% of patients receiving etavopivat achieved a hemoglobin increase greater than 1 g/dL at week 24, compared to 7.2% of patients receiving placebo.
Etavopivat is a selective activator of red blood cell pyruvate kinase (PKR), an enzyme involved in glycolysis. Its activation reduces levels of 2,3-diphosphoglycerate and increases adenosine triphosphate production, improving hemoglobin-oxygen affinity and red blood cell membrane integrity. These effects are intended to reduce red blood cell sickling and improve cell survival.
Novo picked up etavopivat in a 2022 buyout of Forma.
The FDA previously granted etavopivat Fast Track, Rare Pediatric Disease, and Orphan Drug designations. Novo expects regulatory decisions in 2027.